Dr Reddy’s has signed an exclusive licensing deal with Australia’s

印度瑞迪博士实验室已经与澳大利亚签署了独家许可协议

Immutep

伊穆特普

to make, develop and distribute the company’s

制作、开发和分发公司的

cancer treatment

癌症治疗

, according to a stock exchange filing on Monday.

，根据周一的证券交易所文件。

The agreement, worth up to almost $350 million, gives Dr Reddy’s the right to distribute eftilagimod alfa, Immutep’s cancer therapy, in all regions except North America, Europe, Japan and Greater China.

这项价值近 3.5 亿美元的协议赋予 Dr Reddy's 在北美、欧洲、日本和大中华区以外的所有地区分销 Immutep 的癌症疗法 eftilagimod alfa 的权利。

Efti is Immutep’s first-in-class immunotherapy that directly activates the immune system to fight cancer. It is being tested in TACTI-004 (KEYNOTE-F91), a Phase III trial for first-line treatment of advanced or metastatic

Efti是Immutep公司的一种新型免疫疗法，可以直接激活免疫系统来对抗癌症。它正在TACTI-004（KEYNOTE-F91）中进行测试，这是一项针对晚期或转移性癌症一线治疗的III期试验。

non-small cell lung cancer

非小细胞肺癌

. Efti is also being studied for other uses, including head and neck cancer, breast cancer and soft tissue sarcoma.

Efti 还在被研究用于其他用途，包括头颈部癌症、乳腺癌和软组织肉瘤。

Dr Reddy’s shares swung between gains and losses on BSE Sensex in initial trade, before plunging to day's low of Rs 1,267.50 apiece.

在早盘交易中，Dr Reddy's股票在BSE Sensex指数上波动，涨跌互现，随后暴跌至每股1,267.50卢比的当日低点。

Under the licensing deal, Immutep will receive major milestone payments and can retain a large share of future gains in the licensed markets as efti moves towards commercial use. Immutep will also keep global manufacturing rights for the drug and will supply it to Dr Reddy’s in the licensed regions, while keeping full rights in the key markets of North America, Europe and Japan..

根据许可协议，Immutep将获得重要的里程碑付款，并且随着efti朝着商业应用迈进，公司可以在授权市场中保留未来收益的很大一部分。Immutep还将保有该药物的全球生产权，并向Dr Reddy's在授权区域内供应药物，同时在北美、欧洲和日本等关键市场保留全部权利。

Live Events

现场活动

As part of the agreement, Immutep will get an upfront payment of $20 million from Dr Reddy’s. It may also receive further regulatory, development and commercial milestone payments of up to $349.5 million, along with double-digit royalties on future sales in these markets,

根据协议，Immutep将获得Dr Reddy's支付的2000万美元首付款，并可能获得高达3.495亿美元的进一步监管、开发和商业里程碑付款，以及这些市场未来销售额的两位数特许权使用费。

Dr Reddy's

雷迪博士实验室

said in exchange filing.

在交换文件中说。

'This collaboration marks our continuous efforts to deliver first-in-class and innovative therapies for cancer treatment. Efti is a novel immunotherapy with the potential to set a new standard of care in combination with pembrolizumab (Keytruda) and chemotherapy as first-line therapy for non-small cell lung cancer,' said M.V.

“这次合作标志着我们持续努力为癌症治疗提供一流和创新的疗法。Efti 是一种新型免疫疗法，有潜力与派姆单抗（Keytruda）和化疗联用，成为非小细胞肺癌一线治疗的新标准，”M.V. 表示。

Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s..

拉玛纳，首席执行官——品牌市场（印度及新兴市场），雷迪博士实验室。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)